Studio di roll-over per i pazienti che hanno completato un precedente studio su Sabatolimab sponsorizzato da Novartis (MBG453) e sono giudicati dallo sperimentatore beneficiare di un trattamento continuato con Sabatolimab.
Uno studio in aperto, multicentrico, roll-over per pazienti che hanno completato uno studio precedente su Sabatolimab (MBG453) sponsorizzato da Novartis e sono giudicati dallo sperimentatore beneficiare di un trattamento continuato con Sabatolimab.
This study is intended to collect safety data from participants who completed the parent protocols but are still benefiting from study treatment. The study population consists of participants who tolerate study treatment of the parent studies. Collecting safety information from long-term exposure might offer the unique opportunity to detect rare Adverse Events.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
This is a multicenter, open label, roll-over study to collect and assess safety of sabatolimab in participants who are treated in current Novartis-sponsored parent studies and who are benefiting from continued study treatment including sabatolimab as judged by the investigator.
There is no conventional screening period in this study as participants are expected to transition directly from treatment on the parent protocol to treatment on this roll-over protocol. Participants who are candidates for the roll-over protocol will be evaluated by the investigator in the parent protocol for eligibility for the roll-over protocol. If eligible, the parent protocol end of treatment visit will be performed and the informed consent for the roll-over protocol will be signed. Participants then continue treatment on this protocol with the next planned dose of sabatolimab as monotherapy or with other combination agent(s).
The treatment with sabatolimab and combination agent(s), as applicable, is continued according to the schedule in the parent study. Adverse events (AEs) will be collected continuously throughout the study and participants will be questioned about adverse events at each visit.
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Fase
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
Victoria
-
Clayton, Victoria, Australia, 3168
- Novartis Investigative Site
-
-
-
-
Santa Catarina
-
Florianópolis, Santa Catarina, Brasile, 88020-210
- Novartis Investigative Site
-
-
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 1M9
- Novartis Investigative Site
-
-
-
-
-
Prague, Cechia, 128 08
- Novartis Investigative Site
-
-
-
-
-
Tianjin, Cina, 300020
- Novartis Investigative Site
-
-
Jilin
-
Changchun, Jilin, Cina, 130021
- Novartis Investigative Site
-
-
-
-
-
Toulouse, Francia, 31059
- Novartis Investigative Site
-
-
-
-
Baden-Wurttemberg
-
Freiburg im Breisgau, Baden-Wurttemberg, Germania, 79106
- Novartis Investigative Site
-
-
-
-
-
Fukushima, Giappone, 9601295
- Novartis Investigative Site
-
-
-
-
-
Alexandroupoli, Grecia, 681 00
- Novartis Investigative Site
-
Pátrai, Grecia, 265 04
- Novartis Investigative Site
-
-
-
-
BS
-
Brescia, BS, Italia, 25123
- Novartis Investigative Site
-
-
FI
-
Florence, FI, Italia, 50134
- Novartis Investigative Site
-
-
GE
-
Genova, GE, Italia, 16132
- Novartis Investigative Site
-
-
MI
-
Milan, MI, Italia, 20162
- Novartis Investigative Site
-
-
RM
-
Roma, RM, Italia, 00133
- Novartis Investigative Site
-
-
-
-
-
Kuala Lumpur, Malaysia, 59100
- Novartis Investigative Site
-
-
-
-
-
Barcelona, Spagna, 08036
- Novartis Investigative Site
-
Madrid, Spagna, 28009
- Novartis Investigative Site
-
-
Barcelona
-
Badalona, Barcelona, Spagna, 08916
- Novartis Investigative Site
-
-
-
-
Oregon
-
Portland, Oregon, Stati Uniti, 97239
- Oregon Health Sciences University
-
-
Utah
-
Salt Lake City, Utah, Stati Uniti, 84112-0550
- Huntsman Cancer Institute Univ of Utah
-
-
-
-
-
Zurich, Svizzera, 8091
- Novartis Investigative Site
-
-
-
-
-
Izmir, Turchia (Türkiye), 35100
- Novartis Investigative Site
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Participant is currently enrolled in a Novartis-sponsored study with sabatolimab, is being treated with sabatolimab, and has fulfilled all requirements in the parent study.
- Participant is currently benefiting from the treatment with sabatolimab as determined by guidelines of the parent protocol and investigator's judgment.
- Participant has demonstrated compliance, as assessed by the investigator, with the parent study protocol requirements.
- Willingness and ability to comply with scheduled visits, treatment plan and any other study procedures.
- Written informed consent obtained prior to enrolling in the roll-over study.
Exclusion Criteria:
- Participants in cohorts or treatment groups not receiving sabatolimab in the parent protocol.
- Participant has been permanently discontinued from sabatolimab treatment in the parent study due to unacceptable toxicity, non-compliance to study procedures, withdrawal of consent or any other reason.
- Participant currently has unresolved toxicities for which sabatolimab dosing has been interrupted in the parent study (participants meeting all other eligibility criteria may be enrolled once toxicities have resolved to allow sabatolimab dosing to resume).
- Pregnant or nursing (lactating) women. Where pregnancy is defined as the state of a female after conception confirmed by a positive serum hCG laboratory test and until the termination of gestation.
- Participant not willing to comply with the contraception requirements outlined in the exclusion criteria of the parent protocol.
- Local access to commercially available sabatolimab for parent protocol indications.
Other protocol-defined Inclusion/Exclusion may apply.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: sabatolimab + azacitidine
Patients will take sabatolimab 800 mg i.v and azacitidine 75 mg/m2/d d1-7 s.c. or i.v./q4w or sabatolimab 400 mg i.v/q2w and azacitidine 75 mg/m2/d d1-7 s.c. or i.v./q4w. |
Solution for intravenous infusion
Altri nomi:
Solution for subcutaneous injection or intravenous infusion |
|
Sperimentale: sabatolimab + decitabine
Patients will take Sabatolimab 400 mg i.v/q2w and decitabine 20 mg/m2/d d1-5 i.v. |
Solution for intravenous infusion
Altri nomi:
Solution for intravenous infusion |
|
Sperimentale: sabatolimab + venetoclax + azacitidine
Patients will take sabatolimab 200 mg i.v./q2w and venetoclax 400 mg p.o. d1-14/q4wk and azacitidine 75 mg/m2/d d1-7/q4w. |
Solution for intravenous infusion
Altri nomi:
Solution for subcutaneous injection or intravenous infusion Tablet for oral administration |
|
Sperimentale: sabatolimab + spartalizumab + decitabine
Patients will take sabatolimab 400 mg i.v./q2w and decitabine 20 mg/m2/d d1-5 i.v. and spartalizumab 100 mg i.v/q2w. |
Solution for intravenous infusion
Altri nomi:
Solution for intravenous infusion Solution for intravenous infusion
Altri nomi:
|
|
Sperimentale: sabatolimab + HMA
Patients will take sabatolimab 800 mg and azacitidine 75 mg/m2/d d1-7 or decitabine 20 mg/m2/d d1-5/ all q4w HMA means hypomethylating agents. Hypomethylating agents are azacitidine and decitabine. |
Solution for intravenous infusion
Altri nomi:
Tablet for oral administration. HMA = azactidine or decitabine INQOVI = decitabine (oral) |
|
Sperimentale: sabatolimab
Patients will take sabatolimab 800 mg i.v q4w. |
Solution for intravenous infusion
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Lasso di tempo: 5 years
|
An AE is any untoward medical occurrence (e.g. any unfavorable and unintended sign [including abnormal laboratory findings], symptom or disease) in a clinical investigation participant after providing written informed consent for participation in the study. An AE may or may not be temporally or causally associated with the use of a medicinal (investigational) product. An SAE is defined as any adverse event [appearance of (or worsening of any pre-existing)] undesirable sign(s), symptom(s), or medical conditions(s) which meets any one of the following criteria: fatal, life-threatening, results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, may have caused a congenital anomaly/birth defect, requires intervention to prevent permanent impairment or damage. |
5 years
|
|
Severity of AEs and SAEs
Lasso di tempo: 5 years
|
Severity of AEs and SAEs will be measured according to the CTCAE v5.0 |
5 years
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Duration of exposure to sabatolimab
Lasso di tempo: 5 years
|
The length of time patients will be exposed to sabatolimab and will be reported by treatment groups. |
5 years
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Direttore dello studio: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Processi patologici
- Neoplasie
- Malattia cronica
- Attributi della malattia
- Neoplasie per tipo istologico
- Malattie ematologiche
- Leucemia, mieloide
- Malattie mielodisplastiche-mieloproliferative
- Malattie del midollo osseo
- Leucemia
- Condizioni patologiche, segni e sintomi
- Malattie emiche e linfatiche
- Leucemia, mielomonocitica, cronica
- Sindromi mielodisplastiche
- Prodotti chimici organici
- Composti eterociclici, 1-anello
- Composti eterociclici
- Acidi nucleici, nucleotidi e nucleosidi
- Citidina
- Nucleosidi di pirimidina
- Pirimidine
- Composti aza
- Nucleosidi
- Ribonucleosidi
- Decitabina
- Azacitidina
- Venetoclax
- combinazione di droga di decitabina e cedazuridina
- spartilizumab
- Sabatolimab
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- CMBG453B12206B
- 2021-004422-30 (Numero EudraCT)
- 2024-515281-14-00 (Identificatore di registro: EU CTIS)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data is currently available according to the process described on www.clinicalstudydatarequest.com.
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .